CDXC Stock Overview
ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
ChromaDex Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.37 |
| 52 Week High | US$2.24 |
| 52 Week Low | US$1.15 |
| Beta | 1.79 |
| 1 Month Change | -8.67% |
| 3 Month Change | -13.29% |
| 1 Year Change | 13.22% |
| 3 Year Change | -66.01% |
| 5 Year Change | -68.07% |
| Change since IPO | -87.82% |
Recent News & Updates
Recent updates
Market Cool On ChromaDex Corporation's (NASDAQ:CDXC) Revenues
Jun 08
We're Hopeful That ChromaDex (NASDAQ:CDXC) Will Use Its Cash Wisely
Mar 31ChromaDex inks new commercial supply agreement for its Niagen ingredient with Nestlé
Oct 11ChromaDex forms JV in Asia for Tru Niagen; plans to raise $3.1M via stock sale
Oct 03ChromaDex in pact to introduce anti-aging compound in Brazil
Sep 01Ayana Bio appoints Frank Jaksch as CEO
Aug 24ChromaDex wins patent challenge as US regulator rejects Thorne Research's demand to invalidate patent
Aug 15Some ChromaDex Corporation (NASDAQ:CDXC) Analysts Just Made A Major Cut To Next Year's Estimates
Mar 15We're Not Very Worried About ChromaDex's (NASDAQ:CDXC) Cash Burn Rate
Mar 03Companies Like ChromaDex (NASDAQ:CDXC) Can Afford To Invest In Growth
Nov 19When Should You Buy ChromaDex Corporation (NASDAQ:CDXC)?
Sep 14We Discuss Whether ChromaDex Corporation's (NASDAQ:CDXC) CEO Is Due For A Pay Rise
Jun 11ChromaDex to sell Tru Niagen in 3,800 Walmart stores in the U.S.
Jun 07Is There Now An Opportunity In ChromaDex Corporation (NASDAQ:CDXC)?
Jun 02We Think ChromaDex (NASDAQ:CDXC) Can Easily Afford To Drive Business Growth
May 14ChromaDex Corporation 2021 Q1 - Results - Earnings Call Presentation
May 08ChromaDex and Ro partner for Niagen supply
May 04Calculating The Fair Value Of ChromaDex Corporation (NASDAQ:CDXC)
Apr 29ChromaDex inks supply agreement for Niagen
Apr 28ChromaDex Corporation (NASDAQ:CDXC): Is Breakeven Near?
Mar 22Have Insiders Sold ChromaDex Corporation (NASDAQ:CDXC) Shares Recently?
Mar 04At US$18.74, Is ChromaDex Corporation (NASDAQ:CDXC) Worth Looking At Closely?
Feb 26Shareholder Returns
| CDXC | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | -6.8% | -3.9% | -3.1% |
| 1Y | 13.2% | -2.9% | 15.1% |
Return vs Industry: CDXC exceeded the US Life Sciences industry which returned -2.9% over the past year.
Return vs Market: CDXC underperformed the US Market which returned 15.1% over the past year.
Price Volatility
| CDXC volatility | |
|---|---|
| CDXC Average Weekly Movement | 6.1% |
| Life Sciences Industry Average Movement | 7.1% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in US Market | 14.2% |
| 10% least volatile stocks in US Market | 2.5% |
Stable Share Price: CDXC is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: CDXC's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 113 | Rob Fried | https://www.chromadex.com |
ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.
ChromaDex Corporation Fundamentals Summary
| CDXC fundamental statistics | |
|---|---|
| Market Cap | US$103.02m |
| Earnings (TTM) | -US$6.50m |
| Revenue (TTM) | US$80.94m |
1.3x
P/S Ratio-15.9x
P/E RatioIs CDXC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CDXC income statement (TTM) | |
|---|---|
| Revenue | US$80.94m |
| Cost of Revenue | US$32.84m |
| Gross Profit | US$48.10m |
| Other Expenses | US$54.59m |
| Earnings | -US$6.50m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.086 |
| Gross Margin | 59.42% |
| Net Profit Margin | -8.03% |
| Debt/Equity Ratio | 0% |
How did CDXC perform over the long term?
See historical performance and comparison